MetaCap

Vyome (HIND) vs Moleculin Biotech (MBRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vyome is the larger company by market cap ($8.4 million vs $8.2 million), about 1.0 times the size. On valuation, Moleculin Biotech trades at a lower trailing P/E (0.0x vs 0.3x for Vyome).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HIND-41.18%MBRX+1663.50%
+2114%+985%-144%
Oct 7, 20261 yearNov 20, 2026
HIND-42.58%MBRX+1651.13%
+1964%+913%-138%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HIND versus MBRX key metrics
MetricHINDMBRX
Share price$1.20$7.74
Market cap$8.42M$8.22M
1-day change-17.24%-2.40%
YTD return-65.12%—
1-year return-75.90%—
5-year return-100.00%—
P/E ratio (TTM)0.250.04
EPS (TTM)$4.77$179.60
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$319.71K$0
Revenue growth (YoY)+24.43%—
Net income (latest FY)$-10.26M$-33.56M
Gross margin68.43%—
Operating margin-3269.35%—
Net margin-3209.75%—
52-week high$5.88$202.50
52-week low$1.20$3.22
Distance from 52-week high-79.59%-96.18%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+635.83%+55.04%
Average volume13.92K44.66K
Shares outstanding7.02M1.06M
Employees917
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Vyome trades at a higher earnings multiple (0.3x vs 0.0x trailing P/E).

About Vyome

HIND stock →

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

About Moleculin Biotech

MBRX stock →

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

HIND vs MBRX FAQ

Which is bigger, Vyome or Moleculin Biotech?

Vyome (HIND) is larger, with a market capitalization of $8.42M compared with $8.22M for Moleculin Biotech (MBRX).

Which has the lower P/E ratio, HIND or MBRX?

MBRX has the lower trailing P/E at 0.0, versus 0.3 for HIND. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Vyome and Moleculin Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons